secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kalaris Therapeutics, Inc. (KLRS)
CIK:        0001754068
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0001193125-23-202285
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AlloVir Q2 net loss $45.3M; cash $246.5M; three Phase 3 trials on track for H2 2024 data
--------------------------------------------------------------------------------

- Net loss of $45.3M ($0.48 per share) vs $44.6M ($0.69) in Q2 2022.
- Cash, equivalents, and short-term investments $246.5M as of June 30, 2023.
- Closed public offering with gross proceeds ~$75M, extending cash runway into 2025.
- Three Phase 3 registrational trials of posoleucel in allo-HCT patients; data expected H2 2024.
- FY 2023 operating expense guidance $150M-$170M excluding non-cash items.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1754068/000119312523202285/0001193125-23-202285-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1754068/000119312523202285/d533010d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-202285

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer